Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 51

Sort by

Sort Order Select

Journal Articles

Iguratimod plus low-dose rituximab as second-line treatment in adults with primary immune thrombocytopenia: A multicenter, open-label, randomized, controlled, Phase 2 trial

Qiu-Sha Huang, Zhuo-Yu An, Peng Zhao, Qi Chen, Jin Wu, Hai-Xia Fu, Yujun Dong, Hongmei Jing, Liping Dou, Hui Liu, Yi Liu, Lanping Xu, Xiaojun Huang, Xiaohui Zhang

Blood (2025) 146 (Supplement 1): 3044.

https://doi.org/10.1182/blood-2025-3044

Published: 2025

Journal Articles

Lipid metabolism disorders and immune metabolic programming in patients with idiopathic multicentric Castleman disease

Jiaying Ge, Xuejiao Yin, Yi Liu, Shengnan Ding, Qiumei Yao, Li Zhu, Min Yang, Zhenbo Wang, Xiaojun Peng, Tian Tong, Haitao Meng, Hongyan Tong, Liangshun You

Blood (2025) 146 (Supplement 1): 3004.

https://doi.org/10.1182/blood-2025-3004

Published: 2025

Journal Articles

Refined design of a CD117 antibody-drug conjugate safely and effectively conditions non-human primates for autologous transplant-based gene therapy

Blood (2025) 146 (Supplement 1): 5871.

https://doi.org/10.1182/blood-2025-5871

Published: 2025

Journal Articles

Outcome and recovery trajectories for intracerebral hemorrhage in adults with primary immune thrombocytopenia

Peng Zhao, Ming Hou, Yi Liu, Ru Feng, Yujun Dong, Hai-Xia Fu, Qiu-Sha Huang, Jin Wu, Zhuoyu An, Yuanyuan Zhang, Xiangyu Zhao, Ying-jun Chang, Lan-Ping Xu, Xiaojun Huang, Xiaohui Zhang

Blood (2025) 146 (Supplement 1): 3033.

https://doi.org/10.1182/blood-2025-3033

Published: 2025

Journal Articles

Granulocyte maturation and splicing defects in DDX41-mutated leukemia

Blood (2025) 146 (Supplement 1): 1439.

https://doi.org/10.1182/blood-2025-1439

Published: 2025

Journal Articles

Lymphodepletion-free jl-lightning CAR-T targeting CD19/CD22/BCMA achieved 100% CR in 3 Relapsed/Refractory B-NHL patients: A lymphodepletion regimen comparison study

Jinxing Lou, Yan Sun, Shuya Wang, Feiyun Ma, Hongfan Zhu, Xinhong Guan, Zhicai Lin, Yan Gao, Mengxin Xia, Zhifeng Miao, Lijie Rong, Haizhong Zhong, Wenfeng Xu, Yi Liu, Qijun Qian

Blood (2025) 146 (Supplement 1): 4168.

https://doi.org/10.1182/blood-2025-4168

Published: 2025

Journal Articles

A Phase 2, multicenter, open-label, single-arm study assessing a 4-weekly dosing schedule for mogamulizumab in patients with mycosis fungoides/Sézary syndrome (MOGA-2MG-Q4W)

Blood (2025) 146 (Supplement 1): 1875.

https://doi.org/10.1182/blood-2025-1875

Published: 2025

Journal Articles

IFN-γ promotes the progression of iMCD by activating inflammatory monocytes

Blood (2025) 146 (1): 76–88.

https://doi.org/10.1182/blood.2024027689

Published: 2025

Includes: Supplemental data

Journal Articles

NKTR-255 Vs Placebo to Enhance Complete Responses and Durability Following CD19-Directed CAR-T Therapy in Patients with Relapsed/ Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Sairah Ahmed, John F. DiPersio, James H Essell, Catherine S. Diefenbach, Miguel Angel Perales, Cristina Castilla-Llorente, Saurabh Dahiya, Sohail Chaudhry, Heng Xu, Yi Liu, Christie Fanton, Zachary Lee, Mario Q. Marcondes, Mary Tagliaferri, Jonathan Zalevsky, David B. Miklos, Cameron J. Turtle, Joseph P. McGuirk

Blood (2024) 144 (Supplement 1): 2068.

https://doi.org/10.1182/blood-2024-203576

Published: 2024

Journal Articles

Updated Outcome from Biomarker MSC-C5b-9-Guided All-Trans Retinoic Acid Treatment for Resistant/Recurrent ITP: A Multicenter, Randomized, Open-Label, Phase 3 Clinical Trial

Menglin Li, HaiXia Fu, Hui Liu, Ru Feng, Yi Liu, Jingwen Wang, Lei Yang, Zhao Wang, Gaochao Zhang, Qingyuan Qu, Yuxiu Chen, Jianying Zhou, Mengyu Xiao, Lulu Wang, Mengtong Zang, Yun He, Xiaolu Zhu, Xiaosu Zhao, Xiaohui Zhang

Blood (2024) 144 (Supplement 1): 712.

https://doi.org/10.1182/blood-2024-198335

Published: 2024

Journal Articles

DLBCL-Derived HMGB2 Inhibits Macrophage Phagocytosis By up-Regulating TRIM65 to Promote NLRP3 Ubiquitination

Sanxiu He, Yi Liu, Xiaomei Zhang, Li Jun, Huihui Fu, Yifeng Tang, Xiaoqing Xie, Qing Xiao, Liuyue Zhai, Yao Liu

Blood (2024) 144 (Supplement 1): 5768.

https://doi.org/10.1182/blood-2024-206478

Published: 2024

Journal Articles

Efficacy and Safety of a NOVEL ANTI-CD20 Agent (SCT400) in CD20-Positive B-NHL: A Retrospective, Realworld Study in Chongqing, China

Li Jun, Yi Liu, Yong Zhang, Zhanshu Liu, Zailiang Yang, Guofa Xu, Xiaomei Zhang, Yifeng Tang, Chaoyu Wang, Qing Xiao, Xiaoqing Xie, Zailin Yang, Yingyu Nan, Jieping Li, Yao Liu

Blood (2024) 144 (Supplement 1): 6516.

https://doi.org/10.1182/blood-2024-192934

Published: 2024

Journal Articles

Mogamulizumab in Patients with Mycosis Fungoides/Sézary Syndrome: Preliminary Results from an Ongoing Phase 2, Open-Label, Multicenter, Single-Arm Study Assessing a 4-Weekly Dosing Schedule

Blood (2024) 144 (Supplement 1): 3056.

https://doi.org/10.1182/blood-2024-200596

Published: 2024

Journal Articles

Pro-Inflammatory Monocytes As Key Effector Cells in Peripheral Circulatory Inflammatory Storms Driven By IFN-γ and IL-6 Pathways in Imcd

Xuejiao Yin, Yi Liu, Hongyan Tong, Liangshun You

Blood (2024) 144 (Supplement 1): 4685.

https://doi.org/10.1182/blood-2024-207774

Published: 2024

Journal Articles

The remission status of AML patients after allo-HCT is associated with a distinct single-cell bone marrow T-cell signature

Anna Mathioudaki, Xizhe Wang, David Sedloev, Richard Huth, Aryan Kamal, Michael Hundemer, Yi Liu, Spyridoula Vasileiou, Premal Lulla, Carsten Müller-Tidow, Peter Dreger, Thomas Luft, Tim Sauer, Michael Schmitt, Judith B. Zaugg, Caroline Pabst

Blood (2024) 143 (13): 1269–1281.

https://doi.org/10.1182/blood.2023021815

Published: 2024

Includes: Supplemental data

Journal Articles

Influenza Training of Granulopoiesis Promotes Long-Term Anti-Leukemia Activity

Yi Liu, Nianci Chen, Yile Zhou, Li Zhu, Zuopo Lv, Chenying Li, Jiansong Huang, Yanhong Tong, Haitao Meng, Jie Jin, Liangshun You

Blood (2023) 142 (Supplement 1): 3926.

https://doi.org/10.1182/blood-2023-179218

Published: 2023

Journal Articles

Biomarker MSC-C5b-9-Guided Master Therapies for Resistant/Recurrent ITP: A Prospective, Randomized, Open-Label, Multicenter Trial

Menglin Li, Haixia Fu, Yi Liu, Hui Liu, Ru Feng, Zhao Wang, Jingwen Wang, Yuxiu Chen, Qingyuan Qu, Mengyu Xiao, Jianying Zhou, Yun He, Xiaolu Zhu, Yuan Kong, Yingjun Chang, Kaiyan Liu, Xiaohui Zhang

Blood (2023) 142 (Supplement 1): 3951.

https://doi.org/10.1182/blood-2023-182669

Published: 2023

Journal Articles

Inpatient Use of Extended-Release (ER) Opioids for Vaso-Occlusive Crisis Associated with Increased Length of Stay for ER Opioid-Naïve Patients

Madison Canning, Yi Liu, Shruti Gupta, Morgan L. McLemore, Fuad El Rassi

Blood (2023) 142 (Supplement 1): 2507.

https://doi.org/10.1182/blood-2023-179773

Published: 2023

Journal Articles

Improving Anti-Tumor Efficacy of CAR T-Cell Therapy for Acute Myeloid Leukemia (AML): Results from a Multi-Drug Interaction Screening Approach

Julia M. Unglaub, Berit Brinkmann, Qian Chen, David Sedloev, Peter-Martin Bruch, Carolin Kolb, Volker Eckstein, Yi Liu, Anita Schmitt, Simon Raffel, Michael Schmitt, Carsten Müller-Tidow, Junyan Lu, Sascha Dietrich, Tim Sauer

Blood (2023) 142 (Supplement 1): 5969.

https://doi.org/10.1182/blood-2023-181251

Published: 2023

Journal Articles

A Mutation in Complement Factor H (W1183R) Enhances VWF Proteolysis By ADAMTS13 Under Shear

Wenjing Cao, Yi Liu, X. Frank Zhang, X. Long Zheng

Blood (2023) 142 (Supplement 1): 24.

https://doi.org/10.1182/blood-2023-190083

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Iguratimod plus low-dose rituximab as second-line treatment in adults with primary immune thrombocytopenia: A multicenter, open-label, randomized, controlled, Phase 2 trial

Lipid metabolism disorders and immune metabolic programming in patients with idiopathic multicentric Castleman disease

Refined design of a CD117 antibody-drug conjugate safely and effectively conditions non-human primates for autologous transplant-based gene therapy

Outcome and recovery trajectories for intracerebral hemorrhage in adults with primary immune thrombocytopenia

Granulocyte maturation and splicing defects in DDX41-mutated leukemia

Lymphodepletion-free jl-lightning CAR-T targeting CD19/CD22/BCMA achieved 100% CR in 3 Relapsed/Refractory B-NHL patients: A lymphodepletion regimen comparison study

A Phase 2, multicenter, open-label, single-arm study assessing a 4-weekly dosing schedule for mogamulizumab in patients with mycosis fungoides/Sézary syndrome (MOGA-2MG-Q4W)

IFN-γ promotes the progression of iMCD by activating inflammatory monocytes

NKTR-255 Vs Placebo to Enhance Complete Responses and Durability Following CD19-Directed CAR-T Therapy in Patients with Relapsed/ Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Updated Outcome from Biomarker MSC-C5b-9-Guided All-Trans Retinoic Acid Treatment for Resistant/Recurrent ITP: A Multicenter, Randomized, Open-Label, Phase 3 Clinical Trial

DLBCL-Derived HMGB2 Inhibits Macrophage Phagocytosis By up-Regulating TRIM65 to Promote NLRP3 Ubiquitination

Efficacy and Safety of a NOVEL ANTI-CD20 Agent (SCT400) in CD20-Positive B-NHL: A Retrospective, Realworld Study in Chongqing, China

Mogamulizumab in Patients with Mycosis Fungoides/Sézary Syndrome: Preliminary Results from an Ongoing Phase 2, Open-Label, Multicenter, Single-Arm Study Assessing a 4-Weekly Dosing Schedule

Pro-Inflammatory Monocytes As Key Effector Cells in Peripheral Circulatory Inflammatory Storms Driven By IFN-γ and IL-6 Pathways in Imcd

The remission status of AML patients after allo-HCT is associated with a distinct single-cell bone marrow T-cell signature

Influenza Training of Granulopoiesis Promotes Long-Term Anti-Leukemia Activity

Biomarker MSC-C5b-9-Guided Master Therapies for Resistant/Recurrent ITP: A Prospective, Randomized, Open-Label, Multicenter Trial

Inpatient Use of Extended-Release (ER) Opioids for Vaso-Occlusive Crisis Associated with Increased Length of Stay for ER Opioid-Naïve Patients

Improving Anti-Tumor Efficacy of CAR T-Cell Therapy for Acute Myeloid Leukemia (AML): Results from a Multi-Drug Interaction Screening Approach

A Mutation in Complement Factor H (W1183R) Enhances VWF Proteolysis By ADAMTS13 Under Shear

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only